Journals / Osmangazi Tıp Dergisi / 2020 / Cilt: 42 - Sayı: 2

Association Between Alzheimer Disease and APOE Gene Polymorphisms in Turkish Population

Türk Popülasyonunda APOE Polimorfizmleri ve Alzheimer Hastalığı Arasındaki İlişki

Pages
222–230
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On the basis of all these data it can be concluded that the APOE ε4 allele increases the risk of development of AD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of the dementia which is characterized by the accumulation of amyloid plaques at the extracellular compartment and formation of neurofibriller tangles at the intracellular compartment which results in the degeneration of the neuron bodies and synapses.
📊
Key Findings & Data:APOE gene polymorphisms in late-onset AD have a significant effect on cellular levels and also have been associated with neuropathological conditions.
💡
Conclusion & Impact:On the basis of all these data it can be concluded that the APOE ε4 allele increases the risk of development of AD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:: Alzheimer Hastalığı · APOE · polimorfizm

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of the dementia which is characterized by the accumulation of amyloid plaques at the extracellular compartment and formation of neurofibriller tangles at the intracellular compartment which results in the degeneration of the neuron bodies and synapses. APOE gene polymorphisms in late-onset AD have a significant effect on cellular levels and also have been associated with neuropathological conditions. To determine the effect of APOE gene polymorphisms on Alzheimer's patients, we have included 629 AD patients between 45-90 years and 200 healthy subjects into the study. APOE gene isoforms were determined by real-time PCR method. APOE genotype distributions were significantly different between the patient and control groups (p <0.001). There was a statistically significant difference in allele frequencies between patient and control groups (p <0.001). At ε4 allele carriers there was a 5.49 times higher risk of AD than the subjects that lack the ε4 allele (OR= 5.49, %95 CI: 3.86-7.81, p<0.001). The MMSE (Mini-Mental State Examination) score was lower among APOE ε4-carriers when compared to the non-carriers (p<0.001). On the basis of all these data it can be concluded that the APOE ε4 allele increases the risk of development of AD. Our results confirmed that the APOE genotype is a risk factor for AD. However, considering the importance of the geographic location and ethnicity, it is a fact that larger molecular studies are needed to clearly determine the contribution of the APOE gene to the development of AD.

Özet

Alzheimer Hastalığı (AH), demansın en yaygın nedeni olan, sinaps ve nöronların kaybının yanı sıra hücre dışı amyloid plakların ve hücre içi nörofibriler yapıların patolojik oluşumları ile karakterize, en sık görülen progresif nörodejeneratif bir hastalıktır. Geç başlangıçlı AH’da Apolipoprotein E (APOE) gen polimorfizmleri hücresel seviyelerde önemli bir etkiye sahip olmakla beraber aynı zamanda nöropatolojik koşullarla da ilişkilendirilmiştir. APOE gen polimorfizmlerinin AH' ları üzerinde etkisini saptamak amacıyla yaptığımız çalışmamıza 45-90 yaş arasında olan 629 hasta ve 200 sağlıklı birey dahil edilmiştir. APOE geni izoformları gerçek zamanlı polimeraz zincir reaksiyonu (GZ-PZR) yöntemi ile incelenmiştir. Hasta ve kontrol grupları arasında hem APOE genotip dağılımları (p<0.001) hemde allel frekansları (p<0.001) açısından istatistiksel olarak anlamlı farklar tespit edilmiştir. APOE ε4 allel taşıyıcısı olan bireylerde ε4 alleli taşımayan bireylere göre AH riskinin 5.49 kat fazla olduğu sonucuna ulaşılmıştır (OR= 5.49, %95 CI: 3.86-7.81, p<0.001). MMSE (Mini-Mental Durum Muayenesi) skorunun; ε4 alleli taşıyıcılarında, taşıyıcı olmayanlara göre daha düşük olduğu tespit edilmiştir (p<0.001). Bütün bu verilere dayanarak APOE 𝜀4 allelinin AH’nın gelişim riskini arttırdığı sonucuna varılabilir. Sonuçlarımız APOE genotipinin AH için bir risk faktörü olduğunu doğrulamıştır. APOE'nin AH gelişimine katkısını net olarak saptayabilmek için, coğrafi konumun ve etnik kökenin önemi de dikkate alınarak, daha geniş çaplı moleküler çalışmalara ihtiyaç olduğu bir gerçektir.

🔖

Cite This Article

ÇİLİNGİR, O., ADAPINAR, D. Ö., ARAS, B. D., GÖKALP, E. E., ÖZKAN, S., ARSLAN, S., HAZİYEVA, K., KOCAGİL, S., BİLGİN, M., ARTAN, S. (2020). Association Between Alzheimer Disease and APOE Gene Polymorphisms in Turkish Population. Osmangazi Tıp Dergisi, Cilt: 42 - Sayı: 2, 222–230. https://ajindex.com/articles/287900

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cacabelos R, Martínez R, Fernández-Novoa L, Carril JC, Lombardi V, Carrera I, et al. Genomics of dementia: APOE-and CYP2D6-related pharmacogenetics. International Journal of Alzheimer’s Disease. 2012;2012
  2. Association As. 2013 Alzheimer's disease facts and figures. Alzheimer's & dementia. 2013;9(2):208-45
  3. Yu J-T, Tan L, Hardy J. Apolipoprotein E in Alzheimer's disease: an update. Annual review of neuroscience. 2014;37:79-100
  4. Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology. 2013;9(2):106
  5. Association As. 2012 Alzheimer’s disease facts and figures. Alzheimer's & Dementia. 2012;8(2):131-68
  6. Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. Journal of Biological Chemistry. 2009;284(10):6027-31
  7. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774-
  8. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, et al. Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience. 2009;29(21):6771-9
  9. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Science translational medicine. 2011;3(89):89ra57-89ra57
  10. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Aβ accumulation in a new transgenic model of Alzheimer's Disease. Journal of Biological Chemistry. 2012:jbc. M112. 407957
  11. Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype. Acta neuropathologica. 2010;119(5):555-66
  12. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. Journal of Neuroscience. 2012;32(43):15181-92
  13. Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β. Brain. 2012;135(7):2155-68.14. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis.